In this research program we aim to identify and clinically validate targets that are suitable to start pharmaceutical drug screening and further development.
Our specific objectives are as follows:
- To identify and select candidate CVD drug targets with a strong relevance to clinical phenotypes based on molecular and omics data from three unique large-scale population cohorts.
- To further characterize available, and develop new in vitro and in vivo mechanistic and efficacy models that enable the monitoring of the biological function of CVD targets.
- To develop and optimize cutting edge molecular assays to accurately monitor proteins, RNA and metabolites in preclinical and clinical biosamples relevant to CVD.
- To apply molecular assays to further characterize biosamples of two comprehensive well-annotated human CVD biobanks to investigate and validate the contribution of specific pathways to CVD.
- To apply the in vitro and in vivo models and human biobanks to select and prioritise CVD targets.
- To develop and exploit this newly formed pan-European modular pharmaceutical target discovery network in cardiovascular disease.